shares of immunic inc plummeted 62 to 347 in afterhours trading on thursday after it said its psoriasis drug trial had a high placebo rate the company said thursday that preplanned interim analysis in a recent trial of its imu935 for patients with moderatetosevere psoriasis found that reductions in the psoriasis area and severity index in the two active arms didnt separate from placebo at four weeks the overall trial is ongoing and remains blinded the company said immunic is a clinicalstage biopharmaceutical company developing oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases